The Australian biotech company CSL has been delivered a “second strike” by shareholders over its executive pay plans, but has survived a push to spill its board.
Amid frustration over its depressed share price, which fell even further on Tuesday, the blood plasma therapy firm saw more than 40% of votes cast against its executive pay plans at its annual general meeting in Melbourne on Tuesday.